0001522860FALSE00015228602024-06-132024-06-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________
FORM 8-K
_________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2024
_________________________________________
Picture1.jpg
Acutus Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
_________________________________________
Delaware001-3943045-1306615
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
2210 Faraday Ave., Suite 100
Carlsbad, CA
92008
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (442) 232-6080
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.001AFIBN/A
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1

Item 5.07 Submission of Matters to a Vote of Security Holders

On June 13, 2024, Acutus Medical, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Company’s definitive proxy statement for the Annual Meeting was filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 25, 2024 and describes in detail both of the two proposed voting matters (the “Proposals”) submitted to the Company’s stockholders at the Annual Meeting. The final results for the votes cast with respect to each Proposal are set forth below.

As of April 15, 2024, the record date of the Annual Meeting, there were 29,721,542 outstanding shares of the Company’s common stock. At the Annual Meeting, a quorum of 17,339,487 shares of the Company’s common stock were represented in person or by proxy.

Proposal 1

The stockholders elected each of John Sheridan and Niamh Pellegrini, as a Class I director to hold office until the 2027 Annual Meeting of Stockholders, and in each case until their respective successors are duly elected and qualified, by the following vote:

NomineeVotes ForVotes WithheldBroker Non-Votes
John Sheridan7,107,884540,9209,690,683
Niamh Pellegrini7,063,972584,8329,690,683

Proposal 2

The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following vote:

Votes ForVotes AgainstAbstentions
16,567,457 674,776 97,254

No other items were presented for stockholder approval at the Annual Meeting.


Item 9.01.    Financial Statements and Exhibits.
(d)Exhibits
Exhibit
Number
Description
104.0Cover Page Interactive Data File (embedded within the Inline XBRL document)
2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Acutus Medical, Inc.
Date: June 14, 2024By:
/s/ Takeo Mukai
Takeo Mukai
Chief Executive Officer & Chief Financial Officer
3
v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 13, 2024
Entity Registrant Name Acutus Medical, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39430
Entity Tax Identification Number 45-1306615
Entity Address, Address Line One 2210 Faraday Ave.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92008
City Area Code 442
Local Phone Number 232-6080
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol AFIB
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001522860
Amendment Flag false
Acutus Medical (NASDAQ:AFIB)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Acutus Medical Charts.
Acutus Medical (NASDAQ:AFIB)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Acutus Medical Charts.